Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy - PubMed (original) (raw)
. 2006 Nov;70(5):1575-84.
doi: 10.1124/mol.106.026716. Epub 2006 Aug 10.
Affiliations
- PMID: 16901982
- DOI: 10.1124/mol.106.026716
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy
Ségolène Galandrin et al. Mol Pharmacol. 2006 Nov.
Abstract
Drug efficacy is typically considered an intrinsic property of a ligand/receptor couple. However, recent observations suggest that efficacy may also be influenced by the signaling effectors engaged by a unique receptor. To directly and systematically test this possibility, we assessed the ability of a panel of beta-adrenergic ligands to modulate the activity of two effector systems, the adenylyl cyclase (AC) and the mitogen-activated protein kinase (MAPK), via beta(1) and beta(2) adrenergic receptors. Although some compounds displayed similar efficacies toward the two pathways, others showed complex efficacy profiles. For example, compounds that are inverse agonists for the AC activity were found to be either agonists, neutral antagonists, or inverse agonists for the MAPK pathway. Likewise, agonists for the AC were either agonists or neutral antagonists for MAPK. Given this complexity, we propose a Cartesian representation of the efficacies that takes into account the activities of the different effectors that can be engaged by a given receptor. In addition, compounds considered as nonselective for beta(1) and beta(2) adrenergic receptors, based on their binding affinities, showed distinct relative efficacy profiles toward AC and MAPK, adding a new dimension to the concept of ligand selectivity. Taken together, the results suggest that binding of different ligands promote distinct conformational changes leading to specific signaling outcomes. Our data therefore clearly illustrate that efficacy is a pluridimensional parameter that is not an intrinsic characteristic of a ligand/receptor couple. This should have important implications for the future design of screening assays used in drug discovery campaigns.
Comment in
- Missing links: mechanisms of protean agonism.
Neubig RR. Neubig RR. Mol Pharmacol. 2007 May;71(5):1200-2. doi: 10.1124/mol.107.034926. Epub 2007 Feb 9. Mol Pharmacol. 2007. PMID: 17293557
Similar articles
- Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor.
Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M. Galandrin S, et al. Mol Pharmacol. 2008 Jul;74(1):162-72. doi: 10.1124/mol.107.043893. Epub 2008 Apr 10. Mol Pharmacol. 2008. PMID: 18403719 - β-Adrenergic agonists mediate enhancement of β1-adrenergic receptor N-terminal cleavage and stabilization in vivo and in vitro.
Hakalahti AE, Khan H, Vierimaa MM, Pekkala EH, Lackman JJ, Ulvila J, Kerkelä R, Petäjä-Repo UE. Hakalahti AE, et al. Mol Pharmacol. 2013 Jan;83(1):129-41. doi: 10.1124/mol.112.080440. Epub 2012 Oct 11. Mol Pharmacol. 2013. PMID: 23066091 - Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
Chidiac P, Nouet S, Bouvier M. Chidiac P, et al. Mol Pharmacol. 1996 Sep;50(3):662-9. Mol Pharmacol. 1996. PMID: 8794908 - The evasive nature of drug efficacy: implications for drug discovery.
Galandrin S, Oligny-Longpré G, Bouvier M. Galandrin S, et al. Trends Pharmacol Sci. 2007 Aug;28(8):423-30. doi: 10.1016/j.tips.2007.06.005. Epub 2007 Jul 19. Trends Pharmacol Sci. 2007. PMID: 17659355 Review. - Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
Gardner OS, Dewar BJ, Graves LM. Gardner OS, et al. Mol Pharmacol. 2005 Oct;68(4):933-41. doi: 10.1124/mol.105.012260. Epub 2005 Jul 14. Mol Pharmacol. 2005. PMID: 16020742 Review.
Cited by
- Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists.
Partyka A, Zagórska A, Kotańska M, Walczak M, Jastrzębska-Więsek M, Knutelska J, Bednarski M, Głuch-Lutwin M, Mordyl B, Janiszewska P, Wesołowska A. Partyka A, et al. PLoS One. 2020 Aug 7;15(8):e0237196. doi: 10.1371/journal.pone.0237196. eCollection 2020. PLoS One. 2020. PMID: 32764777 Free PMC article. - Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).
Ahn KH, Mahmoud MM, Shim JY, Kendall DA. Ahn KH, et al. J Biol Chem. 2013 Apr 5;288(14):9790-9800. doi: 10.1074/jbc.M112.438804. Epub 2013 Feb 28. J Biol Chem. 2013. PMID: 23449980 Free PMC article. - Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.
Kenakin T. Kenakin T. Br J Pharmacol. 2010 Jul;160(5):1045-7. doi: 10.1111/j.1476-5381.2010.00764.x. Br J Pharmacol. 2010. PMID: 20590598 Free PMC article. - The ins and outs of adrenergic signaling.
Lohse MJ. Lohse MJ. J Mol Med (Berl). 2015 Sep;93(9):955-62. doi: 10.1007/s00109-015-1323-x. Epub 2015 Jul 23. J Mol Med (Berl). 2015. PMID: 26199112 Review. - Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.
Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, Ventura S, Ayoub MA, Pfleger KD. Mustafa S, et al. J Biol Chem. 2012 Apr 13;287(16):12952-65. doi: 10.1074/jbc.M111.322834. Epub 2012 Feb 27. J Biol Chem. 2012. PMID: 22371491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases